---
title: "BeOne Medicines posts 2025 results and issues cautious 2026 outlook"
description: "BeOne Medicines Ltd, a biopharmaceutical company based in Switzerland and listed in Hong Kong, has released its unaudited consolidated results for Q4 and audited results for the full year 2025. The co"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277035413.md"
published_at: "2026-02-26T11:55:34.000Z"
---

# BeOne Medicines posts 2025 results and issues cautious 2026 outlook

> BeOne Medicines Ltd, a biopharmaceutical company based in Switzerland and listed in Hong Kong, has released its unaudited consolidated results for Q4 and audited results for the full year 2025. The company provided a cautious financial outlook for 2026, emphasizing that the guidance is preliminary and subject to change due to clinical and regulatory risks. The latest analyst rating for BeOne Medicines (HK:6160) is a Buy, with a price target of HK$290.00. The company focuses on hematology and innovative therapies, aligning its reporting with U.S. GAAP and international standards.

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

An update from BeOne Medicines Ltd ( (HK:6160) ) is now available.

BeOne Medicines Ltd., a Switzerland-based biopharmaceutical group listed in Hong Kong, develops innovative drug candidates with a focus on hematology and other specialty therapies. The company is expanding globally and aligns its reporting with both U.S. GAAP and international listing standards, reflecting its dual-market regulatory and investor base.

The company released unaudited consolidated results for the fourth quarter and audited results for the full year ended 31 December 2025, along with 2026 financial guidance and business updates prepared under U.S. GAAP. Management cautioned investors that the guidance is based on preliminary assessments, may differ from IFRS-based figures to be disclosed by 31 March 2026, and should be treated carefully given clinical, regulatory and commercial risks highlighted in its risk disclosures.

The most recent analyst rating on (HK:6160) stock is a Buy with a HK$290.00 price target. To see the full list of analyst forecasts on BeOne Medicines Ltd stock, see the HK:6160 Stock Forecast page.

**More about BeOne Medicines Ltd**

BeOne Medicines Ltd. is a Switzerland-incorporated biopharmaceutical company listed in Hong Kong, focused on developing and commercializing hematology and other innovative medicines. The group operates globally and reports its financials under U.S. GAAP, while also complying with Hong Kong listing requirements and SEC disclosure rules.

**Average Trading Volume:** 3,313,309

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$348B

### Related Stocks

- [513120.CN - GF CSI HK Innovative Drugs Industry ETF(QDII)](https://longbridge.com/en/quote/513120.CN.md)
- [06160.HK - BEONE MEDICINES](https://longbridge.com/en/quote/06160.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 诺和诺德 UBT251 在华二期临床数据亮眼，减重效果近 20% | 诺和诺德授权药 UBT251 中国二期临床数据亮眼：用药 24 周体重最高减 19.7%（安慰剂仅 2%），公司称 “非常受鼓舞”。但受 Cagrisema 负面消息拖累，股价仍跌超 4%。诺和诺德已支付 2 亿美元首付款，总交易或达 20 | [Link](https://longbridge.com/en/news/276728466.md) |
| ADMA 生物制药｜8-K：2025 财年营收 5.1 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/276939538.md) |
| 百济神州｜10-K：2025 财年营收 53.43 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/277028656.md) |
| 顶尖卓越医疗以 1.003 亿港元收购在线医疗平台的关联交易 | 顶尖卓越医疗集团有限公司将以 1 亿港元收购顶尖卓越二有限公司 100% 的股份，此交易属于香港上市规则下的关联交易。此次收购使顶尖卓越能够整合来自中国大陆互联网医疗实体的财务业绩。由于卖方是控股股东的子公司，因此需要独立股东的批准。已成立 | [Link](https://longbridge.com/en/news/277135842.md) |
| Nexus Precision Health 收购 Leal Health 以加速大规模的精准医疗 | Nexus Precision Health 已收购 Leal Health，这是一款基于人工智能的患者决策支持平台，旨在增强精准医疗。该集成平台连接了超过 250,000 名患者、40,000 名临床医生和 90 家生物制药合作伙伴，旨在 | [Link](https://longbridge.com/en/news/276923592.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.